Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma

Clinicians routinely prescribe adjuvant chemotherapy (ACT) for resected non-small cell lung cancer patients. However, ACT only improves five-year disease-free survival in stage I-III non-small cell lung cancer by 5-15%, with most patients deriving no benefit. Herein, deregulation of the E2F pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lu, Kurtyka, Courtney A, Welsh, Eric A, Rivera, Jason I, Engel, Brienne E, Muñoz-Antonia, Teresita, Yoder, Sean J, Eschrich, Steven A, Creelan, Ben C, Chiappori, Alberto A, Gray, Jhanelle E, Ramirez, Jose Luis, Rosell, Rafael, Schabath, Matthew B, Haura, Eric B, Chen, Dung-Tsa, Cress, Douglas W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347689/
https://www.ncbi.nlm.nih.gov/pubmed/27756884
http://dx.doi.org/10.18632/oncotarget.12672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347689/
https://www.ncbi.nlm.nih.gov/pubmed/27756884
http://dx.doi.org/10.18632/oncotarget.12672

Ejemplares similares